Maharashtra FDA Cancels and Later Withdraws Cipla Pune Unit Licence Over Regulatory Violations
The Maharashtra Food and Drug Administration (FDA) cancelled the drug sale licences of Cipla Pharma Life Sciences Ltd's Carry and Forwarding unit in Pune on August 27, citing serious irregularities in packaging, storage, stock records, and recall procedures related to Reactin Plus Tablets. The FDA found unauthorised promotional claims, improper storage, discrepancies in inventory, and incomplete recall compliance. Stock worth Rs 11.19 lakh was seized. Cipla challenged the order, and the Bombay High Court criticised the FDA's procedure, leading to the withdrawal of the cancellation and a directive for a fresh show-cause notice and reasoned order.
First-hand measurement across 15 sources
We measured how 15 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 55%, Right 45%). Overall sentiment is neutral (44/100). Lens Score 57/100.
Outlets measured: republicworld, indiatoday, freepressjournal, hindustantimes, timesnow, theassamtribune, economictimes, freepressjournal, and 7 more. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
All 1 outlets scored close to centre on political lean. The real divergence here is in emphasis, not lean — compare the headlines below to see how each outlet chose to frame the same facts.
Sentiment was consistent across outlets (35–52/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
zeenews broke this story on 28 Aug, 03:41 pm. Other outlets followed.